Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyMichèle Cavo, Michele Baccarani, Patrizia Tosi et al.|Journal of Clinical Oncology|2007Cited by 374
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patientsMelina Verso, Sergio Bertoglio, Giancarlo Agnelli et al.|Internal and Emergency Medicine|2008Cited by 126
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, Claudia Cellini et al.|The Lancet Haematology|2020Cited by 58
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Luciano Masini, Raffaella Marcheselli et al.|Leukemia & lymphoma/Leukemia and lymphoma|2011Cited by 28
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDMAnnamaria Brioli, Michèle Cavo, Annalisa Pezzi et al.|Blood|2014Cited by 3